Damora Therapeutics (DMRA) Return on Capital Employed (2020 - 2026)
Damora Therapeutics' (DMRA) quarterly Return on Capital Employed came in at 63.9% in Q1 2026, up 6661.0% YoY from 0.95% in Q1 2025, and up 64.98% on a QoQ basis from 182.47% in Q4 2025.
Damora Therapeutics (DMRA) Return on Capital Employed (2020 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 7 years of Return on Capital Employed data on file, last reported at 63.9% in Q1 2026.
- Quarterly Return on Capital Employed rose 6661.0% year-over-year to 63.9% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 63.9% (up 6661.0% YoY) and the FY2025 annual result came in at 177.56%, down 9349.0% from the prior year.
- Return on Capital Employed advanced to 63.9% in Q1 2026, from 182.47% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 51.32% in Q1 2022 to a low of 182.47% in Q4 2025.
- A 5-year average of 107.3% and a median of 104.17% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed sank 7456 bps — and 2026, when it surged 6661 bps.
- Tracing DMRA's Return on Capital Employed over 5 years: stood at 92.03% in 2022, then dropped by 13 bps to 104.17% in 2023, then fell by 12 bps to 116.83% in 2024, then plunged by 56 bps to 182.47% in 2025, then jumped by 65 bps to 63.9% in 2026.
- The last three Return on Capital Employed figures came in at 63.9% (Q1 2026), 182.47% (Q4 2025), and 169.73% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | -52.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -52.87% |
| Mar 31, 2026 | -63.90% |
| Dec 31, 2025 | -182.47% |
| Sep 30, 2025 | -169.73% |
| Jun 30, 2025 | -142.55% |
| Mar 31, 2025 | -130.51% |
| Dec 31, 2024 | -116.83% |
| Sep 30, 2024 | -95.17% |
| Jun 30, 2024 | -101.51% |
| Mar 31, 2024 | -103.61% |
| Dec 31, 2023 | -104.17% |
| Sep 30, 2023 | -111.79% |
| Jun 30, 2023 | -110.64% |
| Mar 31, 2023 | -105.31% |
| Dec 31, 2022 | -92.03% |
| Sep 30, 2022 | -77.86% |
| Jun 30, 2022 | -64.74% |
| Mar 31, 2022 | -51.32% |
| Dec 31, 2021 | -41.95% |
| Sep 30, 2021 | -36.92% |